PHÂN TÍCH CHI PHÍ – HIỆU QUẢ CỦA CLOPIDOGREL BRANDNAME SO VỚI GENERIC TRONG PHÒNG NGỪA BIẾN CỐ TIM MẠCH SAU CAN THIỆP QUA DA Ở NGƯỜI BỆNH HỘI CHỨNG VÀNH CẤP TẠI VIỆT NAM

Abstract

Introduction: Clopidogrel, is an tntiplatelet drug, plays a crucial role in preventing cardiovascular events in patients (pts) with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Objective: To analyze the cost-effectiveness (CEA) of clopidogrel brandname and generic in preventing cardiovascular events after PCI in ACS pts. Methods: A CEA from a social perspective was conducted using a Markov model to estimate the lifetime ICER of pts and input data based on literature review, expert consultation, and cross-sectional cost data for treatment of states at the Ho Chi Minh City Heart Institute in the first half of 2024. Results: The study found that compared to generic clopidogrel, brand-name clopidogrel increased QALYs by 0.012 and increased costs by VND 3.04 million. The ICER was found to be VND 254.10 million/QALY and was cost-effective when compared to the 2023 3GDP payment threshold in Vietnam (VND 305.7 million). One-way sensitivity analysis found that clinical efficacy had the greatest impact on the ICER, and the probability of brand-name clopidogrel being cost-effective was over 50%. Conclusion: Brand-name clopidogrel is cost-effective compared to generic clopidogrel on aspirin regimen in the prevention of cardiovascular events in ACS pts after PCI.